Adverse drug reactions of intravesical instillation therapy for bladder cancer: based on FDA adverse event reporting system
This study observed new adverse event signals, providing important assistance for drug selection in adjuvant therapy for non-muscle invasive bladder cancer postoperatively.
Authors
- Longhua Luo (ORCID: https://orcid.org/0009-0002-0739-1027)
- Zixin Wang (ORCID: https://orcid.org/0009-0008-8831-8713)
- M Chen (ORCID: https://orcid.org/0009-0004-0978-6561)
- Xiang Liu (ORCID: https://orcid.org/0009-0004-0904-8067)
- Xiang Sun (ORCID: https://orcid.org/0009-0004-7409-4158)
- Jiaming Zhou (ORCID: https://orcid.org/0000-0002-0043-3645)
- Cong Peng (ORCID: https://orcid.org/0009-0005-6666-4007)
Institutions
- Nanchang University (CN)
- First Affiliated Hospital of Jiangxi Medical College (CN)
- First Affiliated Hospital of Nanchang University (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-08-19
- DOI
- https://doi.org/10.1080/14740338.2024.2393283
- Citations
- 1
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.35